Cel-Sci Corporation

08/17/2026

CEL-SCI Reports Fiscal Third Quarter 2026 Results

CEL-SCI reported financial results for three months ended June 30, 2026, as well as key recent corporate and clinical developments for Multikine.

08/04/2026

CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit

CEL-SCI study published in peer-reviewed Oral Oncology supports Multikine's biomarker strategy and potential overall survival benefit.

07/13/2026

CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine to Market for Newly Diagnosed Head and Neck Cancer

06/24/2026

CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care

CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care.

06/16/2026

CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy

CEL-SCI advances Multikine immunotherapy for Head and Neck Cancer through dual U.S. registration study and Saudi market entry strategy.

06/12/2026

CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine in Saudi Arabia

CEL-SCI and Saudi Amarox to conduct signing ceremony at BIO 2026 for Strategic Agreement to advance commercialization and distribution of Multikine.

05/18/2026

CEL-SCI Reports Fiscal Second Quarter 2026 Results

CEL-SCI reported financial results for three months ended March 31, 2026, as well as key corporate developments for Multikine.

05/12/2026

CEL-SCI Corporation Announces Pricing of Public Offering

CEL-SCI Corporation Announces Pricing of Public Offering.

05/11/2026

CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia

CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia.

02/18/2026

CEL-SCI is focused on two major value-driving milestones in the near term—starting enrollment in our U.S. FDA confirmatory Registration trial of Multikine in head and neck cancer and advancing Multikine globally in markets including Saudi Arabia.

CEL-SCI reported financial results for three months ended December 31, 2025, as well as key recent clinical and corporate developments.